drugset / Trial / NCT05547542
Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing
Phase 1
Completed
19 enrolled
Cerevel Therapeutics, LLC
National Institute on Drug Abuse (NIDA) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to assess the target occupancy at kappa and mu opioid receptors in the brain after single oral doses of CVL-354 in healthy adult participants.
Timeline
- Start
- 2023-03-02
- Primary completion
- 2024-07-24
- Completion
- 2024-08-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Icalcaprant | Small molecule | 25 mg | Oral |
| Subject | Icalcaprant | Small molecule | 150 mg | Oral |
| Background | [11C]-LY2795050 | Unknown | 740 mbq | Intravenous |
| Background | [11C]-carfentanil | Unknown | 740 mbq | Intravenous |